Kirk Wojno1, John Hornberger2, Paul Schellhammer3, Minghan Dai4, Travis Morgan5. 1. Comprehensive Medical Center, Royal Oak, Michigan. 2. Stanford University School of Medicine, Stanford, California; Cedar Associates LLC, Menlo Park, California. Electronic address: ujch@stanford.edu. 3. Urology of Virginia, Nassawadox, Virginia; Strand Diagnostics, Indianapolis, Indiana. 4. Cedar Associates LLC, Menlo Park, California. 5. Strand Diagnostics, Indianapolis, Indiana.
Abstract
PURPOSE: Inaccurate diagnoses of prostate cancer can result from transposition or contamination of patient biopsy specimens, which are known as specimen provenance complications. We assessed the clinical and economic burden of specimen provenance complications in prostate biopsies in the United States. MATERIALS AND METHODS: We performed a comprehensive, systematic review of the literature to approximate the effect of specimen provenance complications on direct medical costs, patient QALYs and medicolegal costs. Data were extracted from published studies on specimen provenance complications rates, prostate cancer treatment efficacy, treatment cost, litigation/settlement costs after false diagnoses of prostate biopsies and patient quality of life. Sensitivity analysis was done to identify factors that most influenced the outcomes and assess the robustness of the findings. RESULTS: Of the estimated 806,251 primary and secondary prostate biopsies performed annually in the United States 20,322 specimen provenance complications were projected to result in 4,570 clinically meaningful false diagnoses and an expected loss of 634 QALYs. The total burden of specimen provenance complications was projected to exceed $879.9 million or $3,776 per positive cancer diagnosis. This estimate was most sensitive to the indemnity cost per false-positive case and the rate of transpositions at independent reference laboratories. CONCLUSIONS: The societal burden of specimen provenance complications in patients who undergo prostate biopsy exceeds $880 million annually in the United States. This analysis framework may be useful as policy makers, health organizations and researchers seek to decrease false diagnoses of prostate cancer and the consequent effects of delayed or unnecessary treatment. Further study is warranted to quantify the economic burden among additional diseases.
PURPOSE: Inaccurate diagnoses of prostate cancer can result from transposition or contamination of patient biopsy specimens, which are known as specimen provenance complications. We assessed the clinical and economic burden of specimen provenance complications in prostate biopsies in the United States. MATERIALS AND METHODS: We performed a comprehensive, systematic review of the literature to approximate the effect of specimen provenance complications on direct medical costs, patient QALYs and medicolegal costs. Data were extracted from published studies on specimen provenance complications rates, prostate cancer treatment efficacy, treatment cost, litigation/settlement costs after false diagnoses of prostate biopsies and patient quality of life. Sensitivity analysis was done to identify factors that most influenced the outcomes and assess the robustness of the findings. RESULTS: Of the estimated 806,251 primary and secondary prostate biopsies performed annually in the United States 20,322 specimen provenance complications were projected to result in 4,570 clinically meaningful false diagnoses and an expected loss of 634 QALYs. The total burden of specimen provenance complications was projected to exceed $879.9 million or $3,776 per positive cancer diagnosis. This estimate was most sensitive to the indemnity cost per false-positive case and the rate of transpositions at independent reference laboratories. CONCLUSIONS: The societal burden of specimen provenance complications in patients who undergo prostate biopsy exceeds $880 million annually in the United States. This analysis framework may be useful as policy makers, health organizations and researchers seek to decrease false diagnoses of prostate cancer and the consequent effects of delayed or unnecessary treatment. Further study is warranted to quantify the economic burden among additional diseases.
Authors: Jesse F Wang; Margaret A Knoedler; Kimberly A Maciolek; Natasza M Posielski; Vania Lopez; Wade A Bushman; Sara L Best; Dan R Gralnek; Kyle A Richards Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Beatrice S Knudsen; Hyung L Kim; Nicholas Erho; Heesun Shin; Mohammed Alshalalfa; Lucia L C Lam; Imelda Tenggara; Karen Chadwich; Theo Van Der Kwast; Neil Fleshner; Elai Davicioni; Peter R Carroll; Matthew R Cooperberg; June M Chan; Jeffry P Simko Journal: J Mol Diagn Date: 2016-03-03 Impact factor: 5.568
Authors: Erfan Aref-Eshghi; Laila C Schenkel; Peter Ainsworth; Hanxin Lin; David I Rodenhiser; Jean-Claude Cutz; Bekim Sadikovic Journal: Front Oncol Date: 2018-04-23 Impact factor: 6.244